These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
307 related items for PubMed ID: 8339258
1. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts. Gerretsen M, Visser GW, van Walsum M, Meijer CJ, Snow GB, van Dongen GA. Cancer Res; 1993 Aug 01; 53(15):3524-9. PubMed ID: 8339258 [Abstract] [Full Text] [Related]
2. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG. Gerretsen M, Schrijvers AH, van Walsum M, Braakhuis BJ, Quak JJ, Meijer CJ, Snow GB, van Dongen GA. Br J Cancer; 1992 Sep 01; 66(3):496-502. PubMed ID: 1520586 [Abstract] [Full Text] [Related]
3. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA. J Nucl Med; 2000 Dec 01; 41(12):1999-2010. PubMed ID: 11138685 [Abstract] [Full Text] [Related]
4. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. Visser GW, Gerretsen M, Herscheid JD, Snow GB, van Dongen G. J Nucl Med; 1993 Nov 01; 34(11):1953-63. PubMed ID: 8229241 [Abstract] [Full Text] [Related]
5. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics. van Gog FB, Visser GW, Klok R, van der Schors R, Snow GB, van Dongen GA. J Nucl Med; 1996 Feb 01; 37(2):352-62. PubMed ID: 8667076 [Abstract] [Full Text] [Related]
11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W. Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986 [Abstract] [Full Text] [Related]
13. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Pavlinkova G, Booth BJ, Batra SK, Colcher D. Clin Cancer Res; 1999 Sep 01; 5(9):2613-9. PubMed ID: 10499640 [Abstract] [Full Text] [Related]
14. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Maraveyas A, Stafford N, Rowlinson-Busza G, Stewart JS, Epenetos AA. Cancer Res; 1995 Mar 01; 55(5):1060-9. PubMed ID: 7866989 [Abstract] [Full Text] [Related]
15. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC. J Nucl Med; 2004 Feb 01; 45(2):327-37. PubMed ID: 14960657 [Abstract] [Full Text] [Related]
18. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy. Colnot DR, Wilhelm AJ, Cloos J, Roos JC, de Bree R, Quak JJ, Snow GB, van Dongen GA. J Nucl Med; 2001 Sep 01; 42(9):1364-7. PubMed ID: 11535726 [Abstract] [Full Text] [Related]